"Once this first manufacturing run is completed successfully, the final stage in the process--testing those capsules and the live cells inside that make up the Cell-in-a-Box technology--can begin. The capsules will be placed into syringes and then those syringes will be frozen and stored in a freezer at Austrianova's manufacturing facility in Thailand. Soon thereafter, a representative sample of the Cell-in-a-Boxsyringes will be thawed and a series of tests (release testing) will begin. These FDA-required tests are necessary for PharmaCyte to be able to use its product in human beings in a clinical trial."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.